1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsRare Disease Research Grants is sponsored by Children's Rare Disease Organization. This organization invites proposals for rare pediatric disease research focused on innovative research into the causes, cures, and treatments of these conditions.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Skip to in this section menu Medical products for rare diseases and conditions Grant Programs to Support Development of Medical Products for Rare Diseases Grant Programs to Support Development of Medical Products for Rare Diseases Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Receipt Dates: October 21, 2025; October 20, 2026; October 19, 2027 (for new applications and resubmissions) FOA Number: RFA-FD-25-020 Funding Opportunity Purpose: The purpose of this Notice of Funding Opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions.
Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development. Learn more about this program: Clinical Trials Grants Program .
Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases Receipt Dates: February 10, 2026; February 8, 2028 (for new applications and resubmissions) FOA Number: RFA-FD-25-017 Funding Opportunity Purpose: The purpose of this notice of funding opportunity (NOFO) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs.
Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development. Learn more about this program: Natural History Studies Grant Program .
Rare Neurodegenerative Disease Grants Program Opportunities Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required Receipt Dates: October 21, 2025 FOA Number: RFA-FD-25-001 Funding Opportunity Purpose: The purpose of this notice of funding opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults.
Through the support of collaborative, efficient and innovative clinical trials, FDA hopes to exert a broad and positive impact by increasing the number of approved medical products for rare neurodegenerative diseases. See instructions and helpful hints (PDF) for applying for rare neurodegenerative disease grants. Learn more about this program: Rare Neurodegenerative Disease Grants Program .
According to the current listing, eligibility includes: Organizations dedicated to rare pediatric disease research. Confirm the full requirements in the official notice before applying.
Rare Disease Research Grants is funded by Children's Rare Disease Organization. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Anthropic is giving rare-disease researchers and early-stage biotechs up to $50,000 in Claude API credits over six months — not cash, but compute. Here is how the two-track program works, who is eligible, what the credits can and cannot do, and how it fits a fast-growing new category: the compute-as-grant model reshaping how AI-for-science actually gets funded.
Read articleThe Department of Energy's Office of Critical Minerals and Energy Innovation is spending to break America's 95% dependence on foreign rare earths. The strategy is unusual: recover critical materials from the waste streams of coal plants, smelters, and refineries that already exist. Here is the full funding architecture — the $75M just awarded, the $500M battery-materials round, the $1B pipeline behind them — and how an industrial operator should position for what comes next.
Read articleOn June 2, 2026, the Department of Energy's Office of Critical Minerals and Energy Innovation selected two demonstration-scale facilities — Phoenix Tailings (with MIT and the University of Minnesota) for $66 million, and the Colorado School of Mines (with ElementUSA, PNNL, Principal Mineral, and Rare Earth Technologies Inc.) for the balance — under the Rare Earth Elements Demonstration Facility Program. Both projects pull rare earths from industrial waste — red mud at the Gramercy refinery in Louisiana, and a mix of mine and refining tailings elsewhere. Here is what the selections tell researchers, small businesses, and downstream magnet customers about where DOE thinks the chokepoint actually is, and what to do before the next demonstration-scale solicitation opens.
Read article